Similar articles

• Use of a new mucolytic agent, ascumist, in postoperative patients.

  Polk JW, Daneswar A, Medina M. Polk JW, et al. Eye Ear Nose Throat Mon. 1969 Mar;48(3):154-8. Eye Ear Nose Throat Mon. 1969. PMID: 5777454 No abstract available.
• A comparative study of alevaire and a new mucolytic agent, acumist in postoperative patients.

  Polk JW, Medina M. Polk JW, et al. Eye Ear Nose Throat Mon. 1970 Jul;49(7):321-4. Eye Ear Nose Throat Mon. 1970. PMID: 4921350 Clinical Trial. No abstract available.
• Evaluation of a new mucolytic agent.

  Sabath LD, Sasahara AA, Burleson VA. Sabath LD, et al. Dis Chest. 1966 Jul;50(1):47-56. doi: 10.1016/s0096-0217(15)33020-x. Dis Chest. 1966. PMID: 5947915 No abstract available.
• Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases.

  Disse B. Disse B. Novartis Found Symp. 2002;248:254-72; discussion 272-6, 277-82. Novartis Found Symp. 2002. PMID: 12568499 Review.
• The anatomy, physiology, pharmacology and pathology of tracheobronchial mucus secretion and the use of expectorant drugs in human disease.

  Richardson PS, Phipps RJ. Richardson PS, et al. Pharmacol Ther B. 1978;3(4):441-79. doi: 10.1016/s0306-039x(78)90010-7. Pharmacol Ther B. 1978. PMID: 32559 Review. No abstract available.